Stephen V. Liu, MD / Bhavesh Shah, RPh, BCOP - Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan

1:31:04
 
공유
 

Manage episode 280403501 series 103590
Player FM과 저희 커뮤니티의 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
Go online to PeerView.com/TMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and managed care provide a foundational overview of the mechanism of action of cancer immunotherapies and why this class of agents is different from other oncologic therapies. The panel also explores how immunotherapies have revolutionized the management of cancer over the last few years, particularly the ways in which SCLC management is finally changing. Additionally, the latest research and practical considerations for value assessment of cancer immunotherapies in managed care settings are presented, with specific implications for SCLC. Upon completion of this activity, participants will be able to: Describe the rationale for and potential benefits of integrating immunotherapies and immune-based combination approaches into the SCLC treatment arsenal throughout the disease continuum, Review efficacy and safety findings from key clinical trials assessing immunotherapies and combination approaches across different treatment settings of SCLC, as well as data on potential biomarkers, Incorporate immunotherapies into treatment plans for appropriate patients with SCLC in managed care settings.

319 에피소드